A Study to Assess the Long-term Safety and Efficacy of ASP1941 in Japanese Diabetic Patients
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 3
Locations
Japan
Study Type
Interventional
Intervention
ipragliflozin
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring Blood glucose, ASP1941, Food effect, Diabetes mellitus
Eligibility Criteria
Inclusion Criteria:
- Type 2 diabetic patients for at least 12 weeks
- HbA1c value between 6.5 and 9.5%
- Body Mass Index ( BMI )20.0 - 45.0kg/m2
Exclusion Criteria:
- Type 1 diabetes mellitus patients
- Serum creatinine > upper limit of normal
- Proteinuria (albumin/creatinine ratio > 300mg/g)
- Dysuria and/or urinary tract infection, genital infection
- Significant renal, hepatic or cardiovascular diseases
- Severe gastrointestinal diseases
- Proliferative diabetic retinopathy
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
before meal group
after meal group
Arm Description
ASP1941 will be administered before meal
ASP1941 will be administered after meal
Outcomes
Primary Outcome Measures
HbA1c
Secondary Outcome Measures
Fasting plasma glucose
Fasting serum insulin
Plasma levels of ASP1941 for population PK analysis
Safety assessed by adverse events, vital signs laboratory tests and 12-lead ECGs
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01054092
Brief Title
A Study to Assess the Long-term Safety and Efficacy of ASP1941 in Japanese Diabetic Patients
Official Title
Long-term Study of ASP1941 - A Phase III, Open-Label, Uncontrolled, Monotherapy Study to Assess the Long-term Safety, Tolerability and Efficacy of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus
Study Type
Interventional
2. Study Status
Record Verification Date
May 2019
Overall Recruitment Status
Completed
Study Start Date
January 14, 2010 (Actual)
Primary Completion Date
July 22, 2011 (Actual)
Study Completion Date
July 22, 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Astellas Pharma Inc
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The primary objective of this study is to evaluate the long-term safety of ASP1941 in patients with type 2 diabetes mellitus. The second objectives are to compare the efficacy and pharmacokinetics of ASP1941 administered before or after food intake.
Detailed Description
Subject will be randomized into either ASP1941 before meal or ASP1941 after meal groups. Subjects will undergo a screening period before entering the long-term treatment. Dosage may be increased during the treatment period if subjects fulfill increasing criteria and the investigators adjudicate that no impact for subjects safety.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
Blood glucose, ASP1941, Food effect, Diabetes mellitus
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
182 (Actual)
8. Arms, Groups, and Interventions
Arm Title
before meal group
Arm Type
Experimental
Arm Description
ASP1941 will be administered before meal
Arm Title
after meal group
Arm Type
Experimental
Arm Description
ASP1941 will be administered after meal
Intervention Type
Drug
Intervention Name(s)
ipragliflozin
Other Intervention Name(s)
ASP1941
Intervention Description
oral
Primary Outcome Measure Information:
Title
HbA1c
Time Frame
For 52 weeks
Secondary Outcome Measure Information:
Title
Fasting plasma glucose
Time Frame
For 52 weeks
Title
Fasting serum insulin
Time Frame
For 52 weeks
Title
Plasma levels of ASP1941 for population PK analysis
Time Frame
For 52 weeks
Title
Safety assessed by adverse events, vital signs laboratory tests and 12-lead ECGs
Time Frame
For 52 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Type 2 diabetic patients for at least 12 weeks
HbA1c value between 6.5 and 9.5%
Body Mass Index ( BMI )20.0 - 45.0kg/m2
Exclusion Criteria:
Type 1 diabetes mellitus patients
Serum creatinine > upper limit of normal
Proteinuria (albumin/creatinine ratio > 300mg/g)
Dysuria and/or urinary tract infection, genital infection
Significant renal, hepatic or cardiovascular diseases
Severe gastrointestinal diseases
Proliferative diabetic retinopathy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Use Central Contact
Organizational Affiliation
Astellas Pharma Inc
Official's Role
Study Chair
Facility Information:
City
Chubu
Country
Japan
City
Chugoku
Country
Japan
City
Hokkaido
Country
Japan
City
Kansai
Country
Japan
City
Kantou
Country
Japan
City
Kyushu
Country
Japan
City
Touhoku
Country
Japan
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.
IPD Sharing Time Frame
Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
IPD Sharing Access Criteria
Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
IPD Sharing URL
https://www.clinicalstudydatarequest.com/
Links:
URL
https://www.astellasclinicalstudyresults.com/study.aspx?ID=106
Description
Link to results on Astellas Clinical Study Results website
Learn more about this trial
A Study to Assess the Long-term Safety and Efficacy of ASP1941 in Japanese Diabetic Patients
We'll reach out to this number within 24 hrs